ApoE genotyping as a progression-rate biomarker in phase II disease-modification trials for Alzheimer's disease

Pharmacogenomics J. 2010 Jun;10(3):161-4. doi: 10.1038/tpj.2009.58. Epub 2009 Dec 8.

Authors

D J Stone¹, C Molony, C Suver, E E Schadt, W Z Potter

Affiliation

¹ Molecular Profiling and Research Informatics, Merck Research Laboratories, West Point, PA 19486, USA. [email protected]

PMID: 19997085
DOI: 10.1038/tpj.2009.58

No abstract available

Publication types

Clinical Trial, Phase II
Randomized Controlled Trial

MeSH terms

Aged, 80 and over
Alleles
Alzheimer Disease / drug therapy
Alzheimer Disease / genetics*
Apolipoproteins E / genetics*
Biomarkers / analysis*
Clinical Trials, Phase II as Topic / methods
Cognition / physiology
Disease Progression
Female
Humans
Male

Substances

Apolipoproteins E
Biomarkers